Fundraising FoxAisling Capital — 2015 Investments
4 investments dated 2015 · listed companies and verified rows first · show all
Protagonist is a company that emphasizes a diverse and inclusive corporate culture as central to its innovation, with stated goals of creating wins for its organization and for patients.
BiotechHealthtechMilpitas, US
Dinesh V. Patel, PhD(Executive Officer, Director)Dinesh Patel(President & Chief Executive Officer)
BoardAsish K. Xavier, Ph.D.(Director)Michael Panaccio, Ph.D.(Director)Armen Shanafelt, Ph.D.(Director)Paul F. Truex(Director)
Co-investorsCanaan PartnersJJDCJohnson & Johnson Innovation – JJDCLilly VenturesRA CapitalStarfish Ventures
Scholar Rock is a biopharmaceutical company that develops therapies targeting growth factor proteins to treat serious diseases.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)inTimothy Springer(Director)David Hallal(Chief Executive Officer, Chairman and Director)inAkshay Vaishnaw(President of Research & Development and Director)inR. Keith Woods(Chief Operating Officer)inVikas Sinha(Chief Financial Officer)in
Co-investorsARCH Venture PartnersEcoR1 CapitalPolaris PartnersThe Kraft Group
Aimmune Therapeutics developed desensitization treatments for life-threatening food allergies, including Palforzia, the first FDA-approved peanut allergy treatment.
Co-investorsForesite CapitalLongitude CapitalMenlo Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.